Immuneering Partners with Lilly for Cancer Trial
Immuneering Corporation, a clinical-stage oncology firm dedicated to enhancing cancer patient survival, is embarking on an exciting new journey. The company announced a clinical supply agreement with Eli Lilly and Company to evaluate the efficacy of atebimetinib in tandem with olomorasib, particularly in patients suffering from advanced non-small cell lung cancer (NSCLC).
Exploring Combination Therapies
The agreement aims to support the clinical evaluation of Immuneering’s lead product candidate, atebimetinib (IMM-1-104), in a planned Phase 2 trial. This trial targets patients who exhibit KRAS G12C mutations and have already attempted prior therapies without success.
E.B. Brakewood, the Chief Business Officer of Immuneering, expressed enthusiasm about this collaboration, stating, "This marks our second collaboration announcement of the year, highlighting our commitment to exploring the potential of atebimetinib alongside synergistic anti-cancer therapies. The MAPK pathway remains an area of deep interest, especially for challenging tumor types like NSCLC."
Potential Benefits of the Drug Combination
At the heart of this initiative is the promising combination of atebimetinib and olomorasib, which could provide a comprehensive blockade of the RAS-MAPK signal transduction pathway. Dr. Igor Matushansky, the Chief Medical Officer of Immuneering, noted that preclinical studies point to enhanced tumor regression and prolonged survival in combination therapy compared to monotherapy. This dual-target approach has the potential to represent a significant advancement for patients with limited treatment options.
Research and Development Focus
Immuneering remains committed to the global development and commercialization of atebimetinib. The company is pioneering a new category of cancer treatments termed Deep Cyclic Inhibitors. Currently, atebimetinib is undergoing a Phase 2a trial involving patients with various advanced solid tumors, including pancreatic cancers.
The development pipeline is rich, containing early-stage programs that signal Immuneering's ambition to tackle multiple forms of cancer, therefore expanding treatment options for patients. While challenges exist in oncology research, Immuneering’s innovative strategies aim to push boundaries and uncover new possibilities for therapeutic interventions.
About Immuneering Corporation
Immuneering is more than just a biotech company; it's a mission-driven organization focused on maintaining the lives of cancer patients. The formulation of new medicines through its cutting-edge research reflects its commitment to finding innovative treatments.
Frequently Asked Questions
What is the focus of the collaboration between Immuneering and Lilly?
The collaboration is aimed at evaluating the efficacy of atebimetinib in combination with olomorasib for treating advanced non-small cell lung cancer.
What is atebimetinib?
Atebimetinib (IMM-1-104) is an oral, once-daily dual MEK inhibitor designed to improve treatment durability and tolerability.
What type of patients is the trial targeting?
The trial focuses on patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer who have progressed after prior therapies.
What are Deep Cyclic Inhibitors?
Deep Cyclic Inhibitors are a new class of cancer drugs under development by Immuneering, targeting MAPK pathway-driven tumors.
Who can I contact for more information about Immuneering?
For media inquiries, contact Gina Nugent, and for investor relations, Laurence Watts. They can provide further details about Immuneering's initiatives.
